Extensive, late-stage radiopharmaceutical pipeline
Our core product pipeline, focused on prostate, renal (kidney), glioblastoma (brain) and hematologic cancers (bone marrow conditioning) is based on decades of clinical experience and real patient outcomes.
Our investigational diagnostic products have the potential to guide treatment decisions, while our therapeutic candidates have potential to deliver personalised precision medicine.
Prostate
PSMA1
PHASE 1
PHASE 2
PHASE 3
COMMERCIAL
Small molecule
68Ga
TLX591-CDx (68Ga-PSMA-11, Illuccix®)
Imaging
Antibody
177Lu
TLX591 (177Lu-rosopatamab)
Therapy
Antibody
225Ac
TLX592 (225Ac-RADmAb®)
Therapy (2ndGen)
Small molecule
99mTc
TLX599-CDx (99mTc-iPSMA)*
Imaging / Surgery
Small molecule
68Ga
TLX591-Sx (68Ga-PSMA-IRDye)
Imaging / Surgery
Kidney
CAIX2
PHASE 1
PHASE 2
PHASE 3
COMMERCIAL
Antibody
89Zr
TLX250-CDx (89Zr-girentuximab)
Imaging
Antibody
177Lu
TLX250 (177Lu-girentuximab)
Therapy
Brain
LAT-13
PHASE 1
PHASE 2
PHASE 3
COMMERCIAL
Small molecule
18F
TLX101-CDx (18F-FET)
Imaging
Small molecule
131I
TLX101 (131I-IPA)
Therapy
BMC/RD4
CD665
PHASE 1
PHASE 2
PHASE 3
COMMERCIAL
Antibody
99mТс
TLX66-CDx (99mTc-besilesomab, Scintimun®)
Imaging
Antibody
90Y
TLX66 (90Y-besilesomab)
Therapy
Shaded sections Indicate expected development stage in the next 12 months.
1. Prostate-specific membrane antigen.
2. Carbonic anhydrase IX.
3. Large amino acid transporter 1.
4. Bone Marrow Conditioning/Rare Diseases.
5. Cluster of differentiation 66.
*Registry Study